Sheets Smith Wealth Management Grows Stock Position in Eli Lilly and Company $LLY

Sheets Smith Wealth Management boosted its position in Eli Lilly and Company (NYSE:LLY) by 4.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,002 shares of the company’s stock after acquiring an additional 579 shares during the quarter. Eli Lilly and Company accounts for approximately 1.8% of Sheets Smith Wealth Management’s portfolio, making the stock its 9th largest holding. Sheets Smith Wealth Management’s holdings in Eli Lilly and Company were worth $16,122,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Thurston Springer Miller Herd & Titak Inc. increased its stake in Eli Lilly and Company by 977.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,777 shares of the company’s stock valued at $8,360,000 after acquiring an additional 7,055 shares during the last quarter. YANKCOM Partnership increased its stake in Eli Lilly and Company by 46.8% in the fourth quarter. YANKCOM Partnership now owns 1,362 shares of the company’s stock valued at $1,464,000 after acquiring an additional 434 shares during the last quarter. Analyst IMS Investment Management Services Ltd. increased its stake in Eli Lilly and Company by 73.9% in the fourth quarter. Analyst IMS Investment Management Services Ltd. now owns 2,541 shares of the company’s stock valued at $2,731,000 after acquiring an additional 1,080 shares during the last quarter. 1900 Wealth Management LLC increased its stake in Eli Lilly and Company by 27.0% in the fourth quarter. 1900 Wealth Management LLC now owns 1,395 shares of the company’s stock valued at $1,499,000 after acquiring an additional 297 shares during the last quarter. Finally, Toth Financial Advisory Corp grew its position in Eli Lilly and Company by 1,690.6% during the fourth quarter. Toth Financial Advisory Corp now owns 1,146 shares of the company’s stock valued at $1,232,000 after acquiring an additional 1,082 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Foundayo, the first once-daily oral GLP‑1 for obesity; Lilly has begun rapid U.S. commercialization and analysts see a multi‑billion-dollar revenue opportunity that helps close the gap with rivals. How to Play Lilly Stock Post Oral Obesity Pill Foundayo’s Approval
• Positive Sentiment: Production capacity ramp: Lilly will manufacture the new oral GLP‑1 at a $6.5B Houston plant, reducing supply risk and supporting commercialization scale-up. This is a tangible capex commitment to grow supply for Foundayo. Eli Lilly’s $6.5B Houston plant will make its new FDA-approved GLP-1 weight loss drug
• Positive Sentiment: Access agreement and M&A broaden growth runway: Lilly announced a U.S. pricing/access arrangement to expand Medicare/Medicaid availability for GLP‑1s and is acquiring Centessa (~$7.8B) to add sleep and neuroscience assets — both support longer‑term revenue diversification. Eli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story
• Positive Sentiment: Investor sentiment lift: Several bullish notes and price-target increases have followed the Foundayo approval, reinforcing upside case for long‑term revenue and margin expansion. Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,294.00
• Neutral Sentiment: Sector M&A/AI tailwinds: Pharma and biotech are accelerating M&A and AI-driven R&D investments; Lilly is participating to both defend and extend its pipeline — positive strategically but benefits will play out over quarters. Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
• Neutral Sentiment: Market narrative around AI and a race to a $1T market cap keeps bullish storytelling alive, but share-price milestones remain dependent on sustained revenue/margin execution and pricing environment. Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First?
• Negative Sentiment: Price competition concerns: Coverage notes a nascent price war in the oral GLP‑1 category that could cap near‑term revenue/margin upside even after approval, pressuring the immediate stock reaction. StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod
• Negative Sentiment: Analyst repositioning: Some research shops have adjusted ratings/positions post-approval (e.g., reclassifications to Buy vs. Strong Buy), suggesting near-term profit‑taking or more cautious multiple expansion assumptions. Eli Lilly and Company (NYSE:LLY) Downgraded to “Buy” Rating by Wall Street Zen

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $925.93 on Tuesday. The stock has a market cap of $874.84 billion, a P/E ratio of 40.35, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51. The firm’s fifty day simple moving average is $990.91 and its 200 day simple moving average is $972.00. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Argus increased their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,222.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.